A phase I/IIa clinical trial of third-generation autologous chondrocyte implantation (IK-01) for focal cartilage injury of the knee

被引:3
|
作者
Matsushita, Takehiko [1 ]
Matsumoto, Tomoyuki [1 ]
Araki, Daisuke [1 ]
Nagai, Kanto [1 ]
Hoshino, Yuichi [1 ]
Niikura, Takahiro [1 ]
Kawamoto, Atsuhiko [2 ]
Go, Masahiro J. [2 ]
Kawamata, Shin [2 ]
Fukushima, Masanori [3 ]
Kuroda, Ryosuke [1 ]
机构
[1] Kobe Univ, Grad Sch Med, Dept Orthoped Surg, Kobe, Hyogo, Japan
[2] Fdn Biomed Res & Innovat Kobe, Kobe, Hyogo, Japan
[3] Fdn Learning Hlth Soc Inst, Nagoya, Aichi, Japan
关键词
Autologous chondrocyte implantation; Third-generation; Knee; PROSPECTIVE MULTICENTER; CHONDRAL DEFECTS; TRANSPLANTATION; REPAIR; MEMBRANE; TISSUE;
D O I
10.1016/j.asmart.2022.03.004
中图分类号
R826.8 [整形外科学]; R782.2 [口腔颌面部整形外科学]; R726.2 [小儿整形外科学]; R62 [整形外科学(修复外科学)];
学科分类号
摘要
Background/objective: The purpose of this study was to report the outcomes of a clinical trial conducted in Japan to assess the safety and effectiveness of third-generation autologous chondrocyte implantation (ACI) using IK-01 (CaReSTM), which does not require flap coverage, in the treatment of patients with focal cartilage injury of the knee.Methods: This was an open label, exploratory clinical trial. Patients were enrolled between June 2012 and September 2016. The primary endpoint of the study was the International Knee Documentation Committee (IKDC) score at 52 weeks after implantation. The IKDC, Lysholm, and visual analog scale (VAS) scores were evaluated at the time of screening and at 4, 12, 24, 36, and 52 weeks after implantation. Improvements from the baseline scores were evaluated using the equation "(postoperative score) - (preoperative score)." Magnetic resonance imaging (MRI) was performed at 2, 12, 24, and 52 weeks after implantation, and MRI measurements were evaluated using T1 rho and T2 mapping.Results: Nine patients were enrolled in this study and were examined for safety. Product quality did not satisfy the specification in one patient, and bacterial joint infection occurred in one patient. As a result, seven patients were included in the outcome analyses. The mean IKDC score significantly improved from 36.4 preoperatively to 74.1% at 52 weeks after implantation (p < 0.0001). The mean Lysholm and VAS scores also significantly improved from 39.6 to 57.4 to 89.6 and 22.9, respectively, after surgery. In the MRI evaluation, the T1 rho and T2 values of the implanted area were similar to those of the surrounding cartilage at 52 weeks after implantation. Conclusions: Third generation ACI (IK-01) can be an effective treatment option for focal cartilage defects of the knee; however, surgeons must pay careful attention to the risk of postoperative joint infection.(c) 2022 Asia Pacific Knee, Arthroscopy and Sports Medicine Society. Published by Elsevier (Singapore) Pte Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/ by-nc-nd/4.0/).
引用
收藏
页码:6 / 12
页数:7
相关论文
共 33 条
  • [31] Long-term T2 and Qualitative MRI Morphology After First-Generation Knee Autologous Chondrocyte Implantation Cartilage Ultrastructure Is Not Correlated to Clinical or Qualitative MRI Outcome
    Salzmann, Gian M.
    Erdle, Benjamin
    Porichis, Stella
    Uhl, Markus
    Ghanem, Nadir
    Schmal, Hagen
    Kubosch, David
    Suedkamp, Norbert P.
    Niemeyer, Philipp
    AMERICAN JOURNAL OF SPORTS MEDICINE, 2014, 42 (08): : 1832 - 1840
  • [32] SCAFFOLD-FREE PELLET-TYPE AUTOLOGOUS CHONDROCYTE IMPLANTATION (CARTILIFE®) FOR FOR THE RESTORATION OF ARTICULAR CARTILAGE DEFECTS: A RANDOMIZED PHASE 2 CLINICAL TRIAL AND EXTENDED 5-YEAR CLINICAL FOLLOW-UP
    Lee, E.
    Kim, H.
    Park, J.
    Yoon, K.
    Lee, J.
    CYTOTHERAPY, 2022, 24 (05) : S156 - S156
  • [33] Third-generation anti-CD19 chimeric antigen receptor T-cells incorporating a TLR2 domain for relapsed or refractory B-cell lymphoma: a phase I clinical trial protocol (ENABLE)
    George, Philip
    Dasyam, Nathaniel
    Giunti, Giulia
    Mester, Brigitta
    Bauer, Evelyn
    Andrews, Bethany
    Perera, Travis
    Ostapowicz, Tess
    Frampton, Chris
    Li, Peng
    Ritchie, David
    Bollard, Catherine M.
    Hermans, Ian F.
    Weinkove, Robert
    BMJ OPEN, 2020, 10 (02):